{"id":"ct-p47-pfs-tocilizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Gastrointestinal perforation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CT-P47 is a biosimilar of tocilizumab, which binds to the IL-6 receptor (both membrane-bound and soluble forms) and inhibits IL-6 signaling. This blocks a key inflammatory cytokine pathway involved in autoimmune and inflammatory conditions. By reducing IL-6-mediated inflammation, it suppresses disease activity in conditions such as rheumatoid arthritis and other inflammatory disorders.","oneSentence":"CT-P47 is a monoclonal antibody that blocks interleukin-6 (IL-6) receptor, reducing inflammatory signaling in immune-mediated diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:07.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Giant cell arteritis"},{"name":"Polyarticular juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT05725434","phase":"PHASE3","title":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Celltrion","startDate":"2023-02-06","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT05188378","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects","status":"UNKNOWN","sponsor":"Celltrion","startDate":"2021-12-22","conditions":"Healthy Subjects","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CT-P47 PFS (tocilizumab)","genericName":"CT-P47 PFS (tocilizumab)","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"CT-P47 is a monoclonal antibody that blocks interleukin-6 (IL-6) receptor, reducing inflammatory signaling in immune-mediated diseases. Used for Rheumatoid arthritis, Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}